Close Menu

NEW YORK — Kaya 17 said last week that it has received the CE mark for its saliva-based SARS-CoV-2 antigen test.

According to the Livermore, California-based company, the point-of-care test detects viral antigens in saliva samples in 15 minutes and runs on a portable, briefcase-sized mobile reader instrument.

Kaya 17 said it intends to pursue Emergency Use Authorization from the US Food and Drug Administration for the test and that it is planning an initial public offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.